Landmark cancer trial shows success against ‘undruggable’ cancer - raising hopes for future treatments
A clinical trial for the experimental drug daraxonrasib has shown significant success in treating advanced pancreatic cancer by targeting previously 'undruggable' RAS proteins. The treatment nearly doubled patient survival rates, offering new hope for aggressive cancer therapies.
Why it matters
This represents a major breakthrough in oncology, potentially changing the standard of care for one of the most lethal and difficult-to-treat forms of cancer.
Heidi Ledford reports for Nature from Seattle, Washington.
The article is a scientific report based on peer-reviewed data and clinical trial results.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in